

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/22, 9/06, 47/38	A1	(11) International Publication Number: WO 90/04964 (43) International Publication Date: 17 May 1990 (17.05.90)
(21) International Application Number: PCT/EP89/01304 (22) International Filing Date: 31 October 1989 (31.10.89) (30) Priority data: 22558 A/88 9 November 1988 (09.11.88) IT (71) Applicant (for all designated States except US): ZAMBON GROUP S.P.A. [IT/IT]; Via della Chimica, 9, I-36100 Vicenza (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): STROPPOLO, Federico [IT/CH]; Via Vedreggio, 17, CH-6963 Pregassona (CH). GAZZANIGA, Annibale [IT/IT]; Via Generale Porro, 22, I-20027 Rescaldina (IT). CASAGRANDE, Cesare [IT/IT]; Via Campogallo, 21/67, I-20020 Arese (IT). (74) Agents: MARCHI, Massimo et al.; Marchi & Mittler s.r.l., Viale Lombardia, 20, I-20131 Milano (IT).		(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i>
(54) Title: PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC USE COMPRISING A WATER SOLUBLE ACID ADDITION SALT OF IBOPAMINE (57) Abstract <p>The solution is buffered at pH 4.5 and comprises from 0.1 to 0.5 parts by weight of hydroxy propyl methyl cellulose for each part by weight of a water soluble pharmaceutically acceptable acid addition salt of ibopamine.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

- 1 -

"Pharmaceutical composition for ophthalmic use comprising a water soluble acid addition salt of ibopamine"

5

DESCRIPTION

The present invention relates to a pharmaceutical composition for ophthalmic use comprising a water soluble pharmaceutically acceptable acid addition salt of ibopamine.

10 More particularly, the present invention relates to a pharmaceutical aqueous solution for ophthalmic use which is buffered at pH 4.5 and comprises both a water soluble pharmaceutically acceptable acid addition salt of ibopamine and hydroxy propyl methyl cellulose.

15 It is well known that ibopamine, i.e. epinine 3,4-O-diisobutyrate, is endowed with mydriatic activity (WO 86/03970).

During intensive studies on the properties of aqueous solutions for ophthalmic use comprising a water soluble pharmaceutically acceptable acid addition salt of ibopamine, it
20 has been found that the aqueous solutions of said ibopamine salts such as, for example, hydrochloride, are stable at room temperature for seven days. At lower temperatures the stability of said solutions is slightly greater; in fact, the stability at $\pm 3^{\circ}\text{C}$ is of 15 days.

25 It has now been found that the stability at room temperature is substantially improved when said solutions are buffered at pH 4.5.

Actually, ibopamine titer in aqueous solutions of ibopamine hydrochloride buffered at pH 4.5 remains substantially
30 unchanged for 20-25 days at room temperature and this period of

- 2 -

time is sufficient to allow administration of the whole content of a conventional container (i.e. a 5-10 ml small bottle).

Table I

1% solution of ibopamine buffered at different pH

5

Stability data

Room Temperature

	1 day	7 days	15 days	20 days
pH 4.5	100%	98%	95%	90%
6	95%	79%	68%	---
7	80%	48%	35%	---

10

Table II

2% solution of ibopamine buffered at pH 4.5

Stability data

Room Temperature

	1 day	7 days	15 days	20 days
pH 4.5	100%	98%	95%	91%

15

In addition, it has been found that the bioavailability of an aqueous solution of a water soluble salt of ibopamine doubles when said solution contains hydroxy propyl methyl cellulose (also sold under the trademark Methocel - Merck Index X ed., pag. 706, No. 4764).

20

The evaluation of the mydriatic effect after administration of 1 drop of 1% ibopamine collyrium containing hydroxy propyl methyl cellulose vs. 2% ibopamine collyrium without hydroxy propyl methyl cellulose has been carried out on 13 patients (6 female and 7 male) whose mean age was 50.2 ± 2.7 years; each patient has been treated (single dose) with both collyria at an interval of 7 days between a treatment and the next one. Posology was 1 drop in the right eye; left eye was not treated (control).

25

30

- 3 -

Pupil diameter was measured with a biomicroscope immediately before (zero time) and 30, 60, and 120 minutes after each treatment.

Local tolerability was evaluated on the basis of the following parameters: appearance and degree of burnings and/or of conjunctival hyperemia.

Table III shows the mean results \pm e.s.. Maximum pupil dilatation was obtained after 30-60 minutes on the average. Meanwhile, the diameter of left eye remained substantially unchanged.

Statistical analysis proves that the two treatments are not significantly different.

Table III

Modification of pupil diameter (mm) after treatment with 1% ibopamine collyrium containing 0.3% of hydroxy propyl methyl cellulose (HPMC) vs. 2% ibopamine collyrium without HPMC.

Mean \pm e.s. in 13 patients

Treatment	Time(minutes)			
	0	30	60	120
1% ibomamine + HPMC	2.39 \pm 0.04	6.55 \pm 0.52	7.90 \pm 0.49	6.79 \pm 0.39
2% ibopamine	2.31 \pm 0.05	6.77 \pm 0.57	7.93 \pm 0.52	6.80 \pm 0.42

Therefore, this invention relates to a pharmaceutical aqueous solution for ophthalmic use comprising a water soluble pharmaceutically acceptable acid addition salt of ibopamine, characterized in that said solution is buffered at pH 4.5 and comprises from 0.1 to 0.5 parts by weight of hydroxy propyl

- 4 -

methyle cellulose for each part by weight of said ibopamine salt.

The solution of this invention will preferably comprise from 0.5 to 5 parts (w/v) of a water soluble pharmaceutically acceptable acid addition salt of ibopamine; even more preferably they will contain from 1 to 2 parts (w/v) of said ibopamine salt.

Ibopamine hydrochloride is a typical example of a water soluble acid addition salt suitable for preparing the solution of this invention.

The solution of this invention may also comprise from 0.001 to 0.2 parts (w/v) of benzalkonium chloride and from 0.2 to 4 parts (w/v) of mannitol. Furthermore, the solution of this invention may comprise from 0.01 to 0.09 parts (w/v) of EDTA.

Suitable compounds for buffering the solution of this invention are, for example, citric acid and disodium phosphate.

The pharmaceutical composition according to the present invention may comprise other excipients suitable for ophthalmic administration and may be prepared according to conventional methods.

Examples of known containers which may be used in connection with the solution of this invention are those enabling the instant preparation of a sterile solution by a patient in need thereof. A typical package will comprise (i) a small bottle containing a sterile powder or a freeze dried powder, (ii) a vial containing a sterile solvent and (iii) a sterile dropper adapted to fit with said bottle after addition of the solvent to the powder.

A combination of a cap reservoir, dropper and bottle may also be used as described in EP-A-217,425.

- 5 -

This invention relates also to a process for preparing a pharmaceutical composition for ophthalmic use, characterized in that said process comprises distributing a sterile dried water soluble pharmaceutically acceptable acid addition salt of ibopamine in a first sterile container and a substantially aqueous sterile solution having pH 4.5 and comprising from 0.1 to 0.5 parts by weight of hydroxy propyl methyl cellulose for each part by weight of said ibopamine salt in a second sterile container, said sterile solution being adapt to form a mydriatic solution when added to said ibopamine salt before administration to a patient in need of a mydriatic effect.

The following compositions and examples are intended to illustrate the present invention without, however, limiting it in any way.

15	Composition 1	
	Ibopamine hydrochloride	1.000 g
	Citric acid monohydrate	0.526 g
	Dibasic sodium phosphate dodecahydrate	1.376 g
	Methocel F4M Premium EP (registered trademark)	0.300 g
20	Benzalkonium chloride	0.010 g
	Mannitol	2.000 g
	Sterile water	q.s. to 100 ml

	Composition 2	
	Ibopamine hydrochloride	1.000 g
25	Citric acid monohydrate	0.520 g
	Disodium phosphate dodecahydrate	1.380 g
	Methocel F4M Premium EP (registered trademark)	0.300 g
	Benzalkonium chloride	0.010 g
	Mannitol	2.000 g
30	EDTA	0.050 g

- 6 -

Sterile water q.s. to 100 ml

Composition 3

Ibopamine hydrochloride 2.000 g
 Citric acid monohydrate 0.351 g
 5 Dibasic sodium phosphate dodecahydrate 0.920 g
 Methocel F4M Premium EP (registered trademark) 0.300 g
 Benzalkonium chloride 0.010 g
 Mannitol 1.333 g
 Sterile water q.s. to 100 ml

10

Example 1

A) Freeze-dried product composition for

	1 vial	1,000 vials
Ibopamine hydrochloride	mg 60	g 60
Mannitol	mg 120	g 120
15 Water for injection	q.s. to ml 1.5	l 1.5

B) Solvent

Hydroxy propyl methyl
 cellulose mg 18 g 18
 20 Citric acid monohydrate mg 31.6 g 31.6
 Disodium hydrogen phosphate
 dodecahydrate mg 82.8 g 82.8
 Benzalkonium chloride mg 0.6 g 0.6
 Water for injection q.s. to ml 6 l 6

25

Ibopamine hydrochloride (60 g) and mannitol (120 g) have
 been dissolved under stirring in 1,500 ml of water for
 injection. The solution has been filtered in sterile conditions
 through a sterile membrane (porosity, 0.2 μ). In a sterile
 room, the solution has been distributed in 1,000 sterile vials
 30 and these vials have been freeze-dried at the following

- 7 -

conditions:

- freezing, plates were cooled at -50°C for 5 hours;
- primary drying, reduced pressure (about $50\ \mu\text{Bar}$) for 1 hour;
plates were then warmed from -50°C to $+20^{\circ}\text{C}$ in 21 hours
(temperature gradient, $0.05^{\circ}\text{C}/\text{min.}$)
- secondary drying, vials have been maintained at $+20^{\circ}\text{C}$ for
five hours, at the end of the treatment the residual pressure
was of about $10\text{--}15\ \mu\text{Bar}$.

Finally, the vials have been plugged in sterile conditions
with sterile closures.

The preparation of vials containing the solvent has been
carried out as follows: hydroxy propyl methyl cellulose has
been dispersed in 2 l of boiling water (for injection). Citric
acid monohydrate, disodium hydrogen phosphate dodecahydrate and
benzalkonium chloride have been added. The remaining water for
injection (4 l) has been cooled and added under stirring and
cooling. The clear and viscous solution has been filtered in
sterile conditions through a sterile membrane (porosity, $0.2\ \mu$).
This solution has been then distributed, in a sterile room,
in 1,000 sterile vials which have been closed with sterile
closures. Finally the vials have been sterilized in a autoclave
at 121°C for 21 minutes.

Example 2

A) Freeze-dried product	composition for	
	1 vial	1,000 vials
Ibopamine hydrochloride	mg 120	g 120
Mannitol	mg 80	g 80
Water for injection	q.s. to ml 2	l 2

B) Solvent

- 8 -

Hydroxy propyl methyl

cellulose	mg	18	g	18
Citric acid monohydrate	mg	21.06	g	21.06
Disodium hydrogen phosphate				
dodecahydrate	mg	55.2	g	55.2
Benzalkonium chloride	mg	0.6	g	0.6
Water for injection	q.s. to ml	6	l	6

The freeze-dried product (A) and the solvent (B) have been prepared in a way similar to that described in example 1.

- 9 -

CLAIMS

1. A pharmaceutical aqueous solution for ophthalmic use comprising a water soluble pharmaceutically acceptable acid addition salt of ibopamine, characterized in that said solution is buffered at pH 4.5 and comprises from 0.1 to 0.5 parts by weight of hydroxy propyl methyl cellulose for each part by weight of said ibopamine salt.

2. A solution according to claim 1, characterized in that Methocel 4M Premium EP is used as hydroxy propyl methyl cellulose.

3. A solution according to any of the preceding claims 1 and 2, characterized in that said solution comprises from 0.001 to 0.02 parts (w/v) of benzalkonium chloride.

4. A solution according to any of the preceding claims from 1 to 3, characterized in that said solution comprises from 0.2 to 4 parts (w/v) of mannitol.

5. A solution according to any of the preceding claims from 1 to 4, characterized in that said solution comprises from 0.01 to 0.09 parts (w/v) of EDTA.

6. A solution according to any of the preceding claims from 1 to 5, characterized in that ibopamine hydrochloride is the water soluble pharmaceutically acceptable acid addition salt of ibopamine.

7. A solution according to claim 6, characterized in that 100 ml of said solution comprise from 0.5 to 5 g of ibopamine hydrochloride.

8. A solution according to claim 7, characterized in that 100 ml of said solution comprise from 1 to 2 g of ibopamine hydrochloride.

- 10 -

9. A solution according to claim 8, characterized in that 100 ml of said solution comprise 0.3 g of Methocel F 4M Premium EP.

5 10. A solution according to claim 8, characterized in that 100 ml of said solution comprise 0.05 g of EDTA.

11. A solution according to claim 8, characterized in that 100 ml of said solution comprise 0.01 g of benzalkonium chloride.

10 12. A solution according to claim 8, characterized in that 100 ml of said solution comprise 2 g of mannitol.

13. A solution according to any of the preceding claims from 1 to 12, characterized in that said solution is instantly preparable by a patient in need thereof.

15 14. A process for preparing a pharmaceutical composition for ophthalmic use, characterized in that said process comprises distributing a sterile dried water soluble pharmaceutically acceptable acid addition salt of ibopamine in a first sterile container and a substantially aqueous sterile solution having pH 4.5 and comprising from 0.1 to 0.5 parts by weight of
20 hydroxy propyl methyl cellulose for each part by weight of said ibopamine salt in a second sterile container, said sterile solution being adapt to form a mydriatic solution when added to said ibopamine salt before administration to a patient in need of a mydriatic effect.

25

30

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 89/01304

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : A 61 K 31/22, A 61 K 9/06, A 61 K 47/38								
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="width: 70%; border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; padding: 5px; vertical-align: top;">IPC⁵</td> <td style="border: 1px solid black; padding: 5px; vertical-align: top;">A 61 K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁵	A 61 K		
Classification System	Classification Symbols							
IPC ⁵	A 61 K							
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category ⁹</th> <th style="width: 60%; border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 30%; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 10px;">X</td> <td style="border: 1px solid black; padding: 10px;"> WO, A, 86/03970 (SIMES) 17 July 1986 see claims; page 6, lines 3-12, 21-25; page 7, lines 1-3; page 7, examples cited in the application ----- </td> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 10px;"> 1, 3-8, 10-13 </td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	WO, A, 86/03970 (SIMES) 17 July 1986 see claims; page 6, lines 3-12, 21-25; page 7, lines 1-3; page 7, examples cited in the application -----	1, 3-8, 10-13
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³						
X	WO, A, 86/03970 (SIMES) 17 July 1986 see claims; page 6, lines 3-12, 21-25; page 7, lines 1-3; page 7, examples cited in the application -----	1, 3-8, 10-13						
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁴</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>								
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search 5th February 1990 </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report 23.02.90 </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;"> International Searching Authority EUROPEAN PATENT OFFICE </td> <td style="border-bottom: 1px solid black; padding: 5px;"> Signature of Authorized Officer <div style="text-align: right; margin-top: 10px;"> T.K. WILLIS </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 5th February 1990	Date of Mailing of this International Search Report 23.02.90	International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer <div style="text-align: right; margin-top: 10px;"> T.K. WILLIS </div>		
Date of the Actual Completion of the International Search 5th February 1990	Date of Mailing of this International Search Report 23.02.90							
International Searching Authority EUROPEAN PATENT OFFICE	Signature of Authorized Officer <div style="text-align: right; margin-top: 10px;"> T.K. WILLIS </div>							

EP 8901304

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 16/02/90. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 8603970	17-07-86	EP-A, B 0205606	30-12-86
		JP-T- 63502270	01-09-88
		US-A- 4764530	16-08-88
